Minerva claims 'positive' PhII data on depression drug while skeptics push stock down
It might have come in a bit of an unorthodox shape, but Minerva Neurosciences says it has a Phase II win in its hands. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
